TScan Therapeutics, Inc. — Director's Dealing 2021

Jul 16, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TScan Therapeutics, Inc. (TCRX)
CIK: 0001783328
Period of Report: 2021-07-15

Reporting Person: Silver Brian M. (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-15	Stock Option (right to buy)	$15.00	A	250441	Acquired	2031-07-14	Voting Common Stock (250441)	Direct

Footnotes

F1: The shares subject to this option will vest with respect to 25% of the shares after 12 months of continuous service to the Issuer following May 3, 2021, and the balance will vest in equal monthly installments over the next 36 months of continuous service to the issuer. If Mr. Silver's employment is terminated without cause or for good reason within the three months prior to a change of control or within 12 months at or following a change of control, any unvested shares or equity awards shall immediately vest.